Skip to main content
. 2020 Aug 19;11(10):2775–2781. doi: 10.1111/1759-7714.13587

Figure 1.

Figure 1

(a) Curve of the metabolic stability of osimertinib in RLMs (n = 3) and (b) Curve of the inhibition ratio of avitinib in RLMs (n = 3).